A Phase 1 interventional study of Ibudilast and Placebo in Migraine Headache, sponsored by Parisa Gazerani. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-12-29.
Sponsored by Parisa Gazerani · Phase 1, Interventional, and Basic science
This will be a double-blind, randomised, placebo-controlled, two period cross over study of ibudilast in the treatment of chronic migraine.
For participants resident in Adelaide, South Australia (i.e. "local participants"):
The study will involve a screening visit followed by eight visits to the Pain and Anaesthesia Research Clinic (PARC), within the Royal Adelaide Hospital (RAH), for baseline testing, initiation of the study medications and ongoing data collection (one baseline and three study visits during each treatment period).
At the baseline visit, blood samples to assess biomarkers (glutamate, calcitonin gene-related peptide, glial fibrillary acidic protein and S100β) will be taken. Patients will then be randomised (in a 1:1 ratio) to commence either ibudilast or placebo treatment, which will continue for 8 weeks. Subsequently participants will undergo a 4-week washout period. At the end of the washout period a second 8-week treatment block with the alternative treatment will commence.
Patients will complete a headache diary daily for at least 4 weeks prior to the baseline visit, throughout the treatment and washout periods and for 4 weeks after treatment ceases. The diary will record headache frequency, duration, intensity, pain characteristics and medication intake for comparison with baseline data.
From screening until the final study visit (over a minimum of 6 months) a total of approximately 200 mL in blood samples will be taken from each local participant.
For participants located in country or interstate locations:
The same study will be undertaken, but instead of attending the Pain and Anaesthesia Research Clinic (PARC), within the Royal Adelaide Hospital (RAH) for screening and study visits, these will be managed remotely through:
basic input from the participant's GP during the screening period correspondence with the PI and study staff via registered post, phone or Skype scheduled visits to the nearest pathology collection centre for blood biochemistry and haematology analysis
Interstate or country participants will also be exempt from collection of blood samples for biomarker analysis, hence a total of approximately 120 mL of blood samples will be taken from each interstate or country participant.
1,528 studies on the registry are indexed under Migraine Disorders; 299 are open to participants now.
This study's enrollment of 33 is below the median of 80 across 1,175 interventional studies indexed under Migraine Disorders.
Browse Migraine Disorders studies →This is the only study on the registry with Parisa Gazerani as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Men and women aged between 18 to 65 years Migraine with or without aura, as diagnosed according to the second edition International Classification of Headache Disorders (ICHD-II) Onset of migraine before 50 years of age Headache on 15 or more days per month Migraine-like headache on 8 or more days per month, as per the IHS guidelines
Exclusion Criteria:
For females of childbearing potential:
Drug: Ibudilast
Drug: Placebo
Ibudilast 40 mg twice daily oral capsules for a duration of 8 weeks
Also known as: Ibudilast (Ketas® 10 mg capsules) manufactured by Kyorin Pharmaceuticals.
Placebo 40 mg twice daily oral capsules for a duration of 8 weeks
Also known as: Pharmaceutical Packaging Professionals, West Thebarton Rd, Thebarton, South Australia
Primary efficacy end point
As suggested by the IHS guidelines for clinical trials in chronic migraine, the primary efficacy endpoint will be number of headache days per month with moderate or severe intensity. Study outcomes will be assessed at baseline and at weeks 2, 4 and 8 of each treatment period. To monitor treatment with ibudilast, blood biochemistry (including assessment of renal and hepatic including GGT function) and haematology will be assessed at baseline, and at weeks 2, 4 and 8 of each treatment period. Patients will also be screened for adverse effects via questionnaire at each visit during treatment.
Time frame: 8 weeks
Secondary efficacy end points
The secondary end points assessed will include: * Migraine frequency (number of days with migraine of any severity/month) * Migraine episode frequency (number of migraine episodes/month) * Medication frequency (number of days acute headache medication taken/month) * Headache related impact on quality of life as assessed using the HIT-6 * Cutaneous allodynia as assessed using the ASC-12 * Biomarker levels
Time frame: 8 weeks
Serum biomarker levels
To determine if serum levels of the following potential biomarkers are able to differentiate response to treatment with ibudilast: glutamate, calcitonin gene-related peptide, glial fibrillary acidic protein and S100 calcium binding protein β.
Time frame: 8 weeks
safety and tolerability of ibudilast
Ibudilast 40 mg or placebo twice daily for 8 weeks is effective and safe in a chronic migraine population.
Time frame: 8 weeks
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.